News >

Radium-223 Plus Anti-VEGF Therapy Reduces Bone Turnover in Advanced RCC

Published: Tuesday, Sep 26, 2017

Dominick Bosse, MD

Dominick Bosse, MD
Patients with advanced renal cell carcinoma (RCC) with bone metastases had reductions in bone-turnover markers (BTMs) when treated with radium-223 dichloride (Xofigo) and a VEGF inhibitor, although the incidence of symptomatic skeletal events (SSEs) remained high, according to findings of a small exploratory study presented at the 2017 ESMO Congress.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x